pING-HER3 Vaccine for Cancer

Purpose of this Study

We are doing this study to find out how an experimental vaccine (pING-hHER3FL) works in your body and against your cancer.

Who Can Participate?

Eligibility

People who have gotten previous treatment with surgery and/or chemotherapy + radiation for one of the following cancers:
  • Breast
  • Colon
  • Lung
  • Prostate
  • Ovarian
  • Cervical
  • Endometrial
  • Gastric (stomach)
  • Pancreatic
  • Bladder
  • Head and neck
  • Liver
  • Esophageal
For more information about who can join this study, please contact the study team at felecia.walton@duke.edu.

What is Involved?

Description

If you choose to join this study, you will:
  • Get the study vaccine three times over 8 weeks
  • Have occasional blood draws for 5 years
  • Have a biopsy to collect tumor tissue, if necessary

Study Details

Full Title

ASSESSING THE IMMUNOGENICITY OF pING-hHER3FL VACCINE IN PATIENTS WITH RESECTED MALIGNANCIES

Principal Investigator

Michael
Morse

Protocol Number

PRO00104093

NCT ID

NCT03832855

Phase

I

Enrollment Status

Open to Enrollment
ClinicalTrials.gov